Envisagenics Raises $2.35M to Expand Work on RNA-based Therapies for Diseases Like SMA
Envisagenics has raised a total of $2.35 million to continue working to discover RNA-based therapies for diseases linked to RNA splicing errors, such as spinal muscular atrophy. The company uses an innovative platform that couples RNA splicing analysis with artificial intelligence. The biotechnology company's drug discovery platform, called SpliceCore, aims to develop therapeutics that correct splicing errors in RNA — the molecule that, along with DNA, gives the instructions to make all the proteins required for our cells to function. Errors in RNA splicing — a natural process cells use to generate a variety of RNA molecules by simply arranging the building blocks that compose the RNA molecule in different ways — are the cause of more than 300 genetic diseases, including SMA. With RNA splicing analysis, researchers are able to analyze millions of RNA sequence codings and identify RNA splicing errors. The most plausible and likely targets for treatments, after being validated in experiments using patients’ data, are then identified by artificial intelligence. With a target identified, researchers can then design a tailored drug and investigate its action, or how well it might work, using the SpliceCore's modular platform. The money was raised in what is called seed capital round, in which an investor funds a company in exchange for an equity stake in it.